Emergent BioSolutions upgraded by The Benchmark Company with a new price target
$EBS
Biotechnology: Pharmaceutical Preparations
Health Care
The Benchmark Company upgraded Emergent BioSolutions from Hold to Buy and set a new price target of $22.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/30/2024 | $15.00 | Buy | H.C. Wainwright |
| 8/22/2024 | $16.00 | Buy | Rodman & Renshaw |
| 3/7/2024 | $5.00 | Hold → Buy | The Benchmark Company |
| 11/20/2023 | Underweight | JP Morgan | |
| 8/29/2023 | Buy → Hold | The Benchmark Company | |
| 4/10/2023 | $22.00 | Hold → Buy | The Benchmark Company |
| 3/17/2023 | $23.00 → $9.00 | Neutral → Underweight | JP Morgan |
| 11/10/2022 | Buy → Hold | The Benchmark Company |
GAITHERSBURG, Md., June 23, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced it has been awarded a $62.4 million contract modification from the Administration for Strategic Preparedness and Response (ASPR), a division of the United States Department of Health and Human Services (HHS) for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)]. The modification has been made to the existing 10-year contract with ASPR (75A50119C00075) whereby Emergent will supply BAT®, an antitoxin used in the treatment of symptomatic botulism following suspected or confirmed exposure to botulinum neurotoxin serotypes A, B, C, D, E, F, or G in both adults and pedi
GAITHERSBURG, Md., June 20, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the Company will be added to the broad-market Russell 3000® Index, effective after the U.S. market closes on June 27, 2025, as part of the annual reconstitution of the Russell U.S. stock indexes. "Inclusion in the Russell 3000® Index is an important milestone in Emergent's ongoing transformation," said Joe Papa, president and chief executive officer of Emergent BioSolutions. "This recognition reflects the positive momentum we are building across the organization and helps to position us to enter a new phase of disciplined, sustainable growth in the year ahead. It also reaffirms our c
Continued commitment to reducing the number of opioid overdose deaths by expanding access, increasing awareness and educating the public about life-saving naloxone GAITHERSBURG, Md., June 05, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) is teaming up with Victoria's Voice Foundation to rally Americans to help save lives from the opioid epidemic on National Naloxone Awareness Day, which honors the late Victoria Siegel and others who have succumbed to overdose. As part of the effort, Victoria's Voice has launched the "Shine. Wear. Share. Care" campaign to raise awareness and provide educational resources to individuals, organizations and businesses that includes a purple
4 - Emergent BioSolutions Inc. (0001367644) (Issuer)
First Quarter 2025 Total Revenues of $222.2 million, decrease of 26% versus prior yearFirst Quarter 2025 Net Income of $68.0 million, increase of 656% versus prior yearFirst Quarter 2025 Gross Margin % of 50% and Adjusted Gross Margin % of 58%, an expansion of 500 bps and 700 bps, respectively, versus prior yearFirst Quarter 2025 Adjusted EBITDA of $77.6 million, increase of 16% versus prior yearFirst Quarter 2025 Adjusted EBITDA Margin of 35% of Total Revenues, an improvement of 1,300 bps versus prior yearReaffirmed FY 2025 Guidance GAITHERSBURG, Md., May 07, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today reported financial results for the first quarter ended March
GAITHERSBURG, Md., April 22, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Wednesday, May 7, 2025, at 5:00 pm eastern time to discuss the financial results for the first quarter of 2025. Participants can access the conference call live via webcast, and also by visiting the Investors page of Emergent's website. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the call can be a
Fourth Quarter 2024 Total Revenues of $194.7 million; Full Year 2024 Total Revenues of $1.04 billionFourth Quarter 2024 Net Loss of $31.3 million, decrease in Net Loss of 37% versus prior yearFourth Quarter 2024 Adjusted EBITDA of $21.0 million, increase of 518% versus prior yearFull Year 2024 Adjusted EBITDA of $183.1 million, compares favorably to a loss of $22.3 million in 2023Guiding to 2025 Adjusted EBITDA of $150 - $200 million and improved gross margins GAITHERSBURG, Md., March 03, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today reported financial results for the quarter and year ended December 31, 2024. "As we close out 2024, I'm proud to share we delivered f
8-K - Emergent BioSolutions Inc. (0001367644) (Filer)
8-K - Emergent BioSolutions Inc. (0001367644) (Filer)
144 - Emergent BioSolutions Inc. (0001367644) (Subject)
4 - Emergent BioSolutions Inc. (0001367644) (Issuer)
4 - Emergent BioSolutions Inc. (0001367644) (Issuer)
4 - Emergent BioSolutions Inc. (0001367644) (Issuer)